Standard Biotools Inc. (NASDAQ: LAB)

Standard BioTools Inc. (LAB) is a life sciences company that operates in the biotechnology industry. The company is dedicated to developing, manufacturing, and selling technologies that aid biomedical researchers in accelerating breakthroughs in human health. Standard BioTools achieves this mission through its proprietary mass cytometry and microfluidics technologies.

Standard BioTools' main business activities revolve around providing life science tools for single-cell proteomics analysis via mass cytometry and tissue imaging, as well as protein detection and analysis technologies for genomics analysis. The company's product portfolio includes preparatory and analytical instruments, consumables, and software. These tools are used in various research applications, including basic research, biomarker discovery, translational research, and clinical research.

The company generates revenue through the sale of its life science tools, which include products for both proteomics and genomics analysis. In the proteomics segment, Standard BioTools offers the CyTOF XT system, a mass cytometry system that performs highly automated high-parameter (>50) single-cell analysis using antibodies conjugated to metal isotopes. This system is used for flow cytometry and tissue imaging applications, enabling the simultaneous detection of up to 40 protein markers in the spatial context of the tissue microenvironment. The Hyperion XTi Imaging System is another product in this segment, which combines mass cytometry technology with imaging capability.

In the genomics segment, the company offers the X9 Real-Time PCR System, a real-time PCR analytical instrument that includes pre-processing steps for microfluidics-based workflows using IFCs. This system is used for genomics analysis, including gene expression and genotyping applications. Additionally, the company offers IFC Controllers and Integrated Fluidic Circuits (IFCs) that incorporate several different types of technology to rapidly design and deploy new microfluidic applications.

Standard BioTools is a leading provider of differentiated multi-omics tools for research, with proprietary mass cytometry and microfluidics technologies as its competitive advantages. These technologies enable high-parameter single-cell analysis and simultaneous detection of multiple protein markers. The company's products are used by pharmaceutical companies, academic and contract research organizations, and government research institutions for drug, disease, and treatment discoveries in various areas, including oncology, diabetes, and cardiovascular, liver, and metabolic diseases.

The company's customers include pharmaceutical companies, academic and contract research organizations, and government research institutions. Standard BioTools has implemented a phased restructuring plan designed to improve efficiencies, expand gross margins, reduce operating costs, and better align its workforce with the current needs of its business. This plan has resulted in significant cost savings and improved profitability.

Standard BioTools' strategy is focused on three key priorities: revenue growth, improving operating discipline through the Standard BioTools Business Systems (SBS), and strategic capital allocation. The company is actively pursuing business development opportunities in the life sciences industry and is committed to leveraging its proprietary technologies to create new revenue opportunities and drive growth.

The company's brand names and/or trade names of its products and services include the CyTOF XT system, the Hyperion XTi Imaging System, the X9 Real-Time PCR System, IFC Controllers, and Integrated Fluidic Circuits (IFCs). These products and services are essential in helping biomedical researchers accelerate breakthroughs in human health, further solidifying Standard BioTools' position as a key player in the life sciences industry.